Outputs (79)

The risk of melanoma in patients with immune-mediated inflammatory diseases exposed to biological therapies: systematic review and meta-analysis (2019)
Presentation / Conference
Esse, S., Mason, K. J., Green, A. C., & Warren, R. B. (2019, July). The risk of melanoma in patients with immune-mediated inflammatory diseases exposed to biological therapies: systematic review and meta-analysis. Poster presented at BRITISH ASSOCIATION OF DERMATOLOGISTS 99TH ANNUAL MEETING, LIVERPOOL, U.K

Biological therapies are used in the treatment of immunemediated inflammatory diseases (IMIDs), including moderateto-severe psoriasis, rheumatoid arthritis (RA), psoriatic arthritis
(PsA) and inflammatory bowel disease (IBD). Melanoma is a
highly i... Read More about The risk of melanoma in patients with immune-mediated inflammatory diseases exposed to biological therapies: systematic review and meta-analysis.

227 Real-world drug discontinuation of acitretin (ACI), ciclosporin (CsA), fumaric acid esters (FAE) and methotrexate (MTX) in patients with moderate-severe psoriasis (2019)
Journal Article
Mason, K. (2019). 227 Real-world drug discontinuation of acitretin (ACI), ciclosporin (CsA), fumaric acid esters (FAE) and methotrexate (MTX) in patients with moderate-severe psoriasis. Journal of Investigative Dermatology, 139(5), S39. https://doi.org/10.1016/j.jid.2019.03.303

Real-world discontinuation of ACI, CsA, FAE and MTX in patients with moderate-severe psoriasis is poorly characterised. The aim of this study was to determine whether treatment history affects the discontinuation rates of these therapies. The British... Read More about 227 Real-world drug discontinuation of acitretin (ACI), ciclosporin (CsA), fumaric acid esters (FAE) and methotrexate (MTX) in patients with moderate-severe psoriasis.

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. (2019)
Journal Article
Warren, R., Marsden, A., Tomenson, B., Mason, K., Soliman, M., Burden, A., …Smith, C. (in press). Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 180(5), 1069 - 1076. https://doi.org/10.1111/bjd.16776

BACKGROUND: Biologic therapies have revolutionized the treatment of moderate-to-severe psoriasis. However, for reasons largely unknown, many patients do not respond or lose response to these drugs. OBJECTIVES: To evaluate demographic, social and clin... Read More about Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study..

Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy (2019)
Journal Article
Yiu, Z., Sorbe, C., Lunt, M., Rustenbach, S., Kühl, L., Augustin, M., …Owen, C. M. (2019). Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. British Journal of Dermatology, 180(4), 894 -901. https://doi.org/10.1111/bjd.17421

BACKGROUND: Patients with psoriasis are often concerned about the risk of serious infection associated with systemic psoriasis treatments. OBJECTIVES: To develop and externally validate a prediction model for serious infection in patients with psoria... Read More about Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy.

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). (2019)
Journal Article
Yiu, Z., Ashcroft, D., Evans, I., McElhone, K., Lunt, M., Smith, C., …Mason, K. (2019). Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology, 180(2), 329 - 337. https://doi.org/10.1111/bjd.17036

BACKGROUND: Patients with psoriasis and clinicians are concerned that infliximab may be associated with a risk of serious infections. OBJECTIVES: To compare the risk of serious infections associated with infliximab in patients with chronic plaque pso... Read More about Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)..

HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis (2018)
Journal Article
Dand, N., Duckworth, M., Baudry, D., Russell, A., Curtis, C. J., Hyuck Lee, S., …Study Group, B. (2019). HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 143(6), 2120-2130. https://doi.org/10.1016/j.jaci.2018.11.038

BACKGROUND: Biologic therapies can be highly effective for the treatment of severe psoriasis, but response for individual patients can vary according to drug. Predictive biomarkers to guide treatment selection could improve patient outcomes and treat... Read More about HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.

A propensity-score weighting approach to compare registry and trial populations of patients with psoriasis on biologic therapies (2018)
Presentation / Conference
Yiu, Z., Mason, K., Barker, J., Hampton, P., McElhone, K., Smith, C., …Burden, D. (2018, August). A propensity-score weighting approach to compare registry and trial populations of patients with psoriasis on biologic therapies. Presented at 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague Congress Centre, Prague, Czech Republic

Background: Previous studies using incomplete trial inclusion and exclusion criteria suggest a difference between the reported effectiveness and safety of biologic therapies between randomised clinical trials (RCT) and real-world populations of patie... Read More about A propensity-score weighting approach to compare registry and trial populations of patients with psoriasis on biologic therapies.

The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared with conventional systemic therapy: Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2018)
Presentation / Conference
Mason, K. J. (2018, August). The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared with conventional systemic therapy: Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Poster presented at 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague Congress Centre, Prague, Czech Republic

Background: Whether psoriasis patients exposed to biologic therapies have an elevated risk of KC (basal cell carcinoma [BCC] or cutaneous squamous cell carcinoma [cSCC]) remains uncertain.

Objectives: To determine whether such patients were at hig... Read More about The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared with conventional systemic therapy: Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Real-world persistence and effectiveness of conventional systemic therapies in the treatment of psoriasis: A systematic review (2018)
Presentation / Conference
Williams, S., Mason, K. J., Yiu, Z., McElhone, K., Warren, R. B., & Griffiths, C. E. (2018, August). Real-world persistence and effectiveness of conventional systemic therapies in the treatment of psoriasis: A systematic review. Paper presented at 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague Congress Centre, Prague, Czech Republic

Background: The effectiveness and persistence of biologic therapies is better understood than more commonly prescribed conventional systemic therapies in clinical practice.

Objectives: To evaluate large-scale observational studies investigating th... Read More about Real-world persistence and effectiveness of conventional systemic therapies in the treatment of psoriasis: A systematic review.

A real-world comparison of effectiveness and safety outcomes between clinical trial eligible and ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2018)
Conference Proceeding
Mason, K. J. (2018). A real-world comparison of effectiveness and safety outcomes between clinical trial eligible and ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Background: There is preliminary evidence that psoriasis patients eligible for clinical trials of biologics are not representative of real-world patients.

Objectives: To determine whether patients enrolled in BADBIR identified as eligible or ineli... Read More about A real-world comparison of effectiveness and safety outcomes between clinical trial eligible and ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR).